Chief Executive Officer (CEO) & Co-founder

Torbjørn is an experienced executive with a broad background within life sciences. He has practiced as a physician in radiology and sports medicine, and transitioned into business as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients. After McKinsey he joined pharma and biotech companies in Aker and eventually became EVP Innovation at Aker BioMarine, where he established and led the innovation department. His latest positions are CFO at Targovax and Lytix Biopharma. Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU).

Chief Technology Officer (CTO) & Co-founder

Sepp has extensive experience in the development and implementation of novel diagnostic and prognostic methods using machine learning within the fields of radiology and pathology. He was central in the development of DoMore Diagnostics’ technology as Senior Developer at the Institute of Cancer Genetics and Informatics at Oslo University Hospital. The work resulted in the first fully automated method predicting prognosis for cancer patients from histopathology images, published in The Lancet. Sepp earned his MSc at Delft University of Technology (NL) and his PhD at Aarhus University (DK).

Head of Quality and Regulatory

Elisabeth has broad experience and background from Quality Assurance in R&D and operations in pharma, biotech and medtech companies. She has been working in GE Healthcare, Life Technologies and Medistim as well as start-up companies responsible for Quality Assurance, Risk Management and Regulatory. Elisabeth holds a Cand Scient (MSc) degree in Biology from University of Oslo.

VP Operations

Andreas has a broad background across science and business functions in life sciences, including R&D and partnering strategy, alliance management, business development, and intellectual property. Prior to joining DoMore Diagnostics, Andreas worked as R&D Director at Aker BioMarine ASA and VP Business Development at Circio Holding ASA (formerly Targovax ASA). Andreas holds an MSc in Experimental Psychology from UNSW Sydney, a PhD in Cognitive Neuroscience and NeuroImaging from the University of Oslo, and was a Fulbright Scholar at the Martinos Center, MGH/Harvard Medical School.

CHAIRMAN

Tomas is a pediatrician with more than 20 years of experience in managing projects and companies within healthcare and the ehealth business. He has served as Medical director and Chief Product Officer in DIPS AS (Enterprise EHR systems) and CEO for PatientSky Norway (Cloud EHR systems). In addition to his medical degree, he holds an MBA in Strategic Management from the Norwegian School of Economics.

DIRECTOR

Øyvind is a serial tech entrepreneur. He’s the Founder and CTO of Exabel, providing AI-as-a-Service within financial markets. Previously he was the Director of Research & Innovation at Medallia, VP at Energy Micro, and Senior Scientist at Brain Corp. Within life sciences, he was an early investor and advisor to OncoImmunity.

Mr. Grotmol holds a Master’s degree in Electronics & computer science from Norwegian University of Science and Technology (NTNU)

DIRECTOR

Yngve is the founder and Chief Investment Officer of impact investment platform Norselab. He is a well-known figure in the Norwegian venture ecosystem and beyond for his role as a co-founder and an investor in several Norwegian tech success stories. His track record includes technology companies like Documaster, Disruptive Technologies, and Skitude. Yngve and his team launched Norselab's first impact-focused growth fund in 2020, building on Norselab's legacy as a co-founder and seed investor dating back to 2015. Norselab currently manages four funds in growth equity, structured equity, and credit.

DIRECTOR

Knut Liestøl is professor and previous department head at the Department of Informatics, University of Oslo. He has also been Research Dean at the Faculty of Mathematics and Natural Sciences, and has long experience as board leader for various research organizations. Prof. Liestøl was a co-leader of the DoMore! project and brings a deep understanding on the technical and scientific aspects of the algorithms. Based on a combined background in statistics, mathematical modelling and biology, his scientific work has focused on methodological aspect in studies on disease etiology and epidemiology, in recent years centered on deep learning for medical decision support in cancer.

DIRECTOR

Ketil brings 20 years of experience from the life science and software industry. In addition to co-founded two start-up companies, he worked for many years in the Norwegian biopharmaceutical company Photocure . He also worked in the software industry for Norwegian KSD Software with logistics technology later acquired by Descartes. Since 2014 Ketil has been Managing Director for Oslo Cancer Cluster, an oncology research and industry cluster.

Keitl holds a few biotech company board positions and was also a member of the health data expert committee from the Ministry of health in 2017. His educational background spans from preclinical medical school to management studies. He also holds an MBA from the University of Cambridge.

John L Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials throughout his career. While he has an interest in many areas of cancer research, his primary focus is on the use of precision medicine in treating cancer. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers. In 2015, Dr. Marshall both established and directed the Precision Oncology Alliance. He currently is serving as the Oncology CMO for Indivumed, creating a global precision medicine research network. Dr. Marshall received his training at Duke University, the University of Louisville, and Georgetown University.

Marco Novelli is professor of gastrointestinal pathology, University College London, Consultant Histopathologist at University College Hospital London and Medical Director at HCA Laboratories, London. He is an internationally recognized expert in gastrointestinal pathology. His research interests include colorectal cancer, Barrett’s oesophagus, inflammatory bowel disease and image analysis/AI. He led the gastrointestinal pathology service at UCLH and was on the UK BCSP National Expert Polyp Panel for many years.

Dr. Takayuki Yoshino, M.D. PhD. currently works at the National Cancer Center Hospital East (NCCE) in Kashiwa, Japan, where he is the Deputy Director of Hospital, Head, Division for the Promotion of Drug and Diagnostic Development and Director for the Department of Gastrointestinal Oncology.

Dr. Yoshino has had over 300 peer-review scholar journal publications on CRC. In addition, he holds several professional appointments, serving on a Guidelines Steering Committee member of ESMO, a chair of Pan-Asian adapted ESMO Guideline for CRC, an advisory committee member of ASCO Breakthrough, the Vice President of JSCO and the administrative board & a chair of international affairs committee of JSMO. He was the first Japanese plenary speaker at ASCO 2022 Annual Meeting (5th /JUN/ 2022).

Jakob Nikolas Kather is a physician specializing in gastrointestinal oncology, and an AI researcher with a university degree in the field of biomedical engineering. He holds a professorship of „Clinical AI“ at the Technical University of Dresden in Germany. Together with his research team, he has been among the global pioneers for biomarker detection in computational pathology since 2016. Their research has recently been published in Nature Medicine and Nature Cancer, among other venues, and has led to the development of several AI methods which are approved for clinical use.

Prof. Dr. med. Hans-Joachim Schmoll is currently leading the clinical oncology research at University Hospital of Halle, Germany.

For decades, Professor Schmoll has been a leader within GI oncology, and was one of the key opinion leaders driving the development of modern testicular cancer treatment. He has been very active in the global oncology community with key positions in ESMO, ASCO, and AIO (Germany). He has been a very active researcher and teacher with numerous publications and book contributions.

Marc Peeters is CEO of the Antwerp University Hospital and Professor of oncology at the Antwerp University. Until November 2021, he was head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp.

Dr. Peeters is co-chair of the colorectal task force of EORTC.

His research interests have included the identification of molecular markers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals and was author and editor of several chapters in oncology books.